1-2 of 2
David Simpson, FRACP, FRCPA, MBChB
Close
Sort by
Journal Articles

A Randomised Dose De-Escalation Safety Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years – End of Recruitment Analysis of Response and Toxicity of the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study

Stephen P Mulligan, MBBS, PhD, FRACP, FRCPA, Devinder S Gill, MB ChB, MRCP (UK), FRCPath (Lond), Paul Turner, MBBS FRACP FRCPA, William E. P. Renwick, MBBS, FRACP, FRCPA, Rosemary Harrup, MB BS, FRACP, FRCPA, Maya Latimer, MBBS, FRACP, FRCPA, Naomi Mackinlay, MB BS, FRACP, FRCPA, Leanne Berkahn, MB ChB, FRACP, FRCPA, David Simpson, FRACP, FRCPA, MBChB, Philip Campbell, MBBS, FRACP, FRCPA, Campbell Tiley, MBBS, FRACP, FRCPA, Gavin Cull, MBBS, DM, FRACP, FRCPA, Marnie Collins, BCom, BSc(Hons), Paul Cortissos, Melanie Sulda, B.Sc, Ph.D., Giles Best, B.Sc., Ph.D., Bryone J Kuss, MBBS, PhD, FRCPA, FRACP
Journal: Blood
Blood (2012) 120 (21): 436.
https://doi.org/10.1182/blood.V120.21.436.436
Published: 2012
Journal Articles

Once Weekly Subcutanous Bortezomib with Cyclophosphamide and Dexamethasone Is Well Tolerated and Effective As Initial Treatment in Symptomatic Multiple Myeloma

David Simpson, FRACP, FRCPA, MBChB, James Liang, MBChB, Ross Henderson, MBChB, PhD, FRACP, FRCPA, Merit Hanna, MBChB, FRCPA, Eileen Merriman, MBChB, FRACP, FRCPA
Journal: Blood
Blood (2012) 120 (21): 4049.
https://doi.org/10.1182/blood.V120.21.4049.4049
Published: 2012